AIM To analyze the impact factors of immune-related cutaneous adverse effects(ircAEs)induced by immune checkpoint inhibitors(ICIs),and to provide a basis for the personalized medication of ICIs in clinical practice.METHODS A total of 379 patients treated with ICIs from December 2021 to December 2023 were included.Among them,79 patients with ircAEs were assigned to the ircAEs group,and 300 patients without ircAEs were assigned to the non-ircAEs group.The gender,age,tumor type,clinical manifestations of ircAEs,treatment regimen,previous medical history,personal history and laboratory examination results were collected to analyze the influencing factors of ircAEs.RESULTS In the ircAEs group,there were 46 males(58.2％)and 33 females(41.8％),with an average age of(60.53±11.18)years.In the group without ircAEs,there were 228 males(76.0％)and 72 females(24.0％),with an average age of(58.5±11.57)years.There were 28 patients(35.4％)aged 61-70 years in the ircAEs group.The most common clinical manifestation of ircAEs was rash(39.2％),followed by rash with itching(21.5％).Binary Logistic regression analysis revealed that gender,treatment regimen,and tumor type were independent risk factors for the occurrence of ircAEs.CONCLUSION Gender,therapeutic regimen,and tumor type emerge as significant predictors of ircAEs.Female patients and those diagnosed with colorectal or biliary tract cancers,particularly when treated with a combination of ICIs and targeted therapies,exhibit a higher propensity for developing ircAEs.The predominant clinical presentations of ircAEs include rash and rash with itching.Therefore,in the clinical administration of ICIs,it is essential to maintain a heightened level of surveillance in patients with the aforementioned risk factors to prevent or reduce the occurrence of ircAEs.
维普
万方数据